• Total revenues of $71.6 million in 2025, up 11% from 2024
• Secured $60 million credit facility with Perceptive Advisors
• Expects 2026 revenue growth of 12-19% to $80-$85 million

AVITA Medical announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, as well as its outlook for fiscal year 2026. The company reported total net revenues of approximately $17.6 million in Q4 2025, compared to $18.4 million in Q4 2024. For the full year 2025, total revenues were approximately $71.6 million, up 11% from $64.3 million in 2024, within the company's revised revenue guidance. AVITA Medical also announced the closing of a five-year, $60 million credit facility with Perceptive Advisors, which will be used to repay existing debt and support the growth of its acute wound care portfolio. The company expects full year 2026 revenue in the range of $80 to $85 million, representing growth of 12% to 19% compared to 2025. Additionally, the company provided updates on the enrollment status of its Cohealyx-I and PermeaDerm-I clinical studies, with data expected later in 2026. The company's interim CEO highlighted the focus on strengthening the business foundation, stabilizing revenue, advancing the clinical pipeline, and improving financial flexibility, positioning AVITA Medical to shift from stabilization to execution-led growth in 2026.

Full year 2026 revenue expected in the range of approximately $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 revenue.

AVITA Medical enters 2026 positioned to shift from stabilization to execution-led growth and deliver more predictable, scaled performance.